OCTALFA

Orphelia Pharma SA is a French pharmaceutical company focused on developing and marketing pediatric formulations of drugs, particularly for epilepsy, neurodegenerative, and metabolic diseases. Founded in 2007 and headquartered in Paris, the company aims to enhance the health and well-being of severely disabled children by creating efficient, reliable, and safe medications with child-friendly formulations. Its product pipeline includes ORP-001, a reformulation of vigabatrin for epilepsy; ORP-002, targeting Rett syndrome; ORP-003, another reformulation of an existing antiepileptic drug; and ORP-006, aimed at treating a specific orphan neonatal epileptic encephalopathy. Orphelia Pharma is dedicated to improving existing medications and developing new pediatric treatments for rare diseases, thereby addressing critical healthcare needs in the pediatric population.

Mathym SAS, a nanotechnology company, engages in developing, manufacturing, commercializing, and licensing colloidal solutions for various industrial purposes worldwide. It develops radiopacifying nanoparticles for use in biomedical materials, such as dental resins or bone graft substitutes. Th company was founded in 2013 and is based in Champagne-Au-Mont-D'Or, France. As of September 30, 2019, Mathym SAS operates as a subsidiary of Baikowski SAS.

Orphelia Pharma SA is a French pharmaceutical company focused on developing and marketing pediatric formulations of drugs, particularly for epilepsy, neurodegenerative, and metabolic diseases. Founded in 2007 and headquartered in Paris, the company aims to enhance the health and well-being of severely disabled children by creating efficient, reliable, and safe medications with child-friendly formulations. Its product pipeline includes ORP-001, a reformulation of vigabatrin for epilepsy; ORP-002, targeting Rett syndrome; ORP-003, another reformulation of an existing antiepileptic drug; and ORP-006, aimed at treating a specific orphan neonatal epileptic encephalopathy. Orphelia Pharma is dedicated to improving existing medications and developing new pediatric treatments for rare diseases, thereby addressing critical healthcare needs in the pediatric population.

Alizé Pharma is a group of privately held biopharmaceutical companies specializing in the development of innovative biopharmaceutical drugs, proteins, and peptides, for the treatment of metabolic diseases and cancer. It is based in Ecully, near Lyon, France. Its management is made up of a team of drug development experts and a board of directors offering wide international experience. Alizé Pharma has two programs, the AZP-3601, a PTH analog for hypoparathyroidism, and AZP-3404, a peptide leveraging the biology of IGFBP2 for the treatment of syndromes of acute insulin resistance. The company was founded on 2015.

Nightswapping is a peer-to-peer accommodation exchange platform that facilitates free stays among its community of over 150,000 members. By allowing users to swap nights in each other's homes, the platform enables travelers to experience authentic local living without the involvement of money, thereby avoiding legal complications associated with traditional rentals. Members can either convert their nights into real money or use them to travel for free, with options available in over 160 countries. Nightswapping also offers personalized travel suggestions for those uncertain about their destination, promoting unique and unexpected travel experiences.

Mathym SAS, a nanotechnology company, engages in developing, manufacturing, commercializing, and licensing colloidal solutions for various industrial purposes worldwide. It develops radiopacifying nanoparticles for use in biomedical materials, such as dental resins or bone graft substitutes. Th company was founded in 2013 and is based in Champagne-Au-Mont-D'Or, France. As of September 30, 2019, Mathym SAS operates as a subsidiary of Baikowski SAS.

e(ye)BRAIN SA is a medical company based in Paris, France, that specializes in the development and manufacturing of eye trackers aimed at diagnosing neurological and psychiatric diseases. Founded in 2008, the company offers two primary products, EyeBrain T1 and EyeBrain T2. The EyeBrain T1 device records eye movements, while the EyeBrain T2 captures both eye and head movements using advanced algorithms. The data collected from these devices is analyzed through the MeyeEval software, which aids in clinical assessments. In addition to its core products, e(ye)BRAIN provides clinical research tools and offers advisory and support services, enhancing the functional exploration of the brain in both healthy and diseased states.

Alizé Pharma is a group of privately held biopharmaceutical companies specializing in the development of innovative biopharmaceutical drugs, proteins, and peptides, for the treatment of metabolic diseases and cancer. It is based in Ecully, near Lyon, France. Its management is made up of a team of drug development experts and a board of directors offering wide international experience. Alizé Pharma has two programs, the AZP-3601, a PTH analog for hypoparathyroidism, and AZP-3404, a peptide leveraging the biology of IGFBP2 for the treatment of syndromes of acute insulin resistance. The company was founded on 2015.

Laboratories JUVISE Pharmaceuticals is a multinational pharmaceutical company that specialises in acquiring, manufacturing and marketing treatments offering great therapeutic potential for patients around the world. Following the sale of Lynapharm laboratories to the Italian pharmaceutical group Sigma-Tau in 2008, Mr Mascha established JUVISE Pharmaceuticals company as an international pharmaceutical subsidiary of the JUVISE group. JUVISE Pharmaceuticals is a pharmaceutical company accredited by the ANSM, French National Agency for the Safety of Medicines and Health Products. The company specialises in manufacturing and marketing pharmaceutical products to treat cardiologic, psychiatric, rheumatic and respiratory/ENT conditions and also fertility/sexual matters. JUVISE Pharmaceuticals currently markets 8 speciality pharmaceutical products: Esidrex®, Sintrom®, Digoxin®, Entumin®, Insidon®, Lumirelax®, Calmixène®, Extovyl®. It also markets two food supplements: Proxeed®Plus and Proxeed®Women. These are sold in a total of 57 countries.

Graftys SAS, based in Aix-en-Provence, France, specializes in the design, development, and manufacturing of synthetic bone biomaterials aimed at reconstructive orthopedic surgery. Founded in 2005, the company provides a range of innovative products, including Graftys QuickSet, a calcium phosphate cement with properties akin to cancellous bone, and biphasic calcium phosphates used for bone repair in surgical procedures. Other offerings include BioActys Granule and Graftys HBS, a cement that transforms into a plastic paste when mixed with a liquid phase. Graftys' products are utilized in various medical applications, such as the fixation of endoprostheses, treatment of bone tumors, and procedures in dentistry and oral surgery, including pulp protection and bone regeneration support.

Orega Biotech SAS is a biotechnology company based in Écully, France, founded in 2010. It specializes in the development of immunotherapeutics for cancer treatment, focusing on the creation of monoclonal antibodies that modulate the activity of regulatory T cells in the tumor microenvironment. The company aims to discover and validate new clinically relevant cancer targets through its target discovery program. Orega Biotech is supported by INSERM-Transfert and OCTALFA, combining scientific expertise with business acumen to advance its innovative therapeutic solutions.

Docea Power SAS specializes in developing and marketing software solutions for power and thermal analysis at the architectural level of electronic systems. Its primary product, Aceplorer, facilitates the modeling, exploration, and optimization of power and thermal behavior across various electronic architectures, accommodating a range of model complexities and heterogeneous systems that include digital, analog, and mixed signal components. Additionally, Docea Power offers AceThermalModeler, which generates compact thermal models for system on chips, 3D integrated circuits, systems in package, or complete boards. The company also provides training and consultancy services to support its clients. Its software is utilized by original equipment manufacturers, system in package and system on chip manufacturers, as well as intellectual property and integrated circuit providers across diverse industries, including wireless, automotive, consumer electronics, aerospace, computing, and medical sectors. Founded in 2006 and headquartered in Moirans, France, Docea Power operates as a subsidiary of Intel Corporation.

Glycode SAS, a biotechnology company, operates in the field of protein glycosylation in France. It provides and licenses GlycodExpress, a yeast based technological platform for the production of recombinant therapeutic glycoproteins for therapeutic purposes, such as antibodies, EPOs, and growth factors, as well as allows humanization of N-glycosylation in Saccharomyces cerevisiae. The company also offers on-demand production and purification services, from the conception and synthesis of optimized expression vectors for protein expression in glycoengineered yeasts to the early steps of production process. Glycode SAS serves biotechnology and pharmaceutical companies. The company was founded in 2004 and is based in Uzerche, France.

Alizé Pharma is a group of privately held biopharmaceutical companies specializing in the development of innovative biopharmaceutical drugs, proteins, and peptides, for the treatment of metabolic diseases and cancer. It is based in Ecully, near Lyon, France. Its management is made up of a team of drug development experts and a board of directors offering wide international experience. Alizé Pharma has two programs, the AZP-3601, a PTH analog for hypoparathyroidism, and AZP-3404, a peptide leveraging the biology of IGFBP2 for the treatment of syndromes of acute insulin resistance. The company was founded on 2015.

Antagene is a French biotechnology company based in Limonest that specializes in the development and sale of DNA tests for animal health, particularly for dogs and cats. The company focuses on detecting genetic diseases and providing genetic profiles to assist in veterinary diagnosis and traceability. By offering a comprehensive range of DNA tests, Antagene enables breeders to select animals that do not carry serious genetic disorders, thereby preventing the propagation of these diseases in future generations. This early detection promotes the overall health and welfare of companion animals, contributing to disease prevention and improving the traceability of animal genetics. As of September 30, 2016, Antagene operates as a subsidiary of CERBA VET.

Alizé Pharma is a group of privately held biopharmaceutical companies specializing in the development of innovative biopharmaceutical drugs, proteins, and peptides, for the treatment of metabolic diseases and cancer. It is based in Ecully, near Lyon, France. Its management is made up of a team of drug development experts and a board of directors offering wide international experience. Alizé Pharma has two programs, the AZP-3601, a PTH analog for hypoparathyroidism, and AZP-3404, a peptide leveraging the biology of IGFBP2 for the treatment of syndromes of acute insulin resistance. The company was founded on 2015.

Ipsogen is develops and markets diagnostic tests in the field of oncology worldwide. The company offers diagnostic kits and biomarkers. Its products are used in the diagnosis, prognosis, and monitoring of patients with leukemia.